(February 7, 2017) An OCRFA funded study, published on January 13, 2017 in Oncotarget, sheds light on EMSY, a gene that researchers at New York University Langone Medical Center now understand to have a role similar to those of BRCA1 and BRCA2. BRCA1 and BRCA2 are well known genes that, when working, help with DNA … Continued
(January 30, 2017) In a study funded in part by OCRFA, and published this month in Oncotarget, researchers, including first author and former OCRFA grantee Petar Jelinic, PhD, studied EMSY, a putative BRCAness gene, and its role in the suppression of DNA damage repair in ovarian cancer cells. The EMSY gene is amplified in approximately … Continued
(January 20, 2017) OCRFA has awarded $5.6 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $75 million. This year’s grants have been awarded to twenty top scientists at thirteen leading medical centers across the country. “Our 2017 grantees are among the best and brightest working … Continued
OCRFA-funded scientists are working hard to save women’s lives. In medical institutions across the country, they investigate the origins and biology of ovarian cancer, find new ways to identify and prevent the disease, and discover better treatments. In 2016, our grantees made significant advances in the fight against ovarian cancer, including: Progress is being made … Continued
(Nov. 3, 2016) Senescence is the state when normal, healthy cells no longer have the ability to divide, which can occur during chemotherapy or when cancer genes within that cell are activated. Senescence can be very useful, for example, when one wants to stop cancer cells from rapidly dividing, but there can be negative side … Continued
(October 31, 2016) Estrogen signaling is a known factor in how certain estrogen receptive (ER positive) tumors grow in breast and ovarian cancers. That signaling, which can promote malignant tumor growth, can sometimes be effectively treated with anti-estrogen therapy, such as tamoxifen. What is less understood, and currently being studied at the Wistar Institute, is … Continued
(October 5, 2016) A team of researchers, including senior author and former OCRFA grantee Rugang Zhang, PhD, have been studying the relationship between PD-1 and PD-L1, a protein and an accompanying molecule, and t-cells, which are a body’s natural defense against tumor growth. PD-L1 can be found on both cancer cells and healthy cells but, … Continued
(June 17, 2016) An OCRFA funded study recently published in Oncogene investigated the role that protein STAT3 plays in the activation and metastasis of ovarian cancer cells. Many women with ovarian cancer develop fluid in the abdomen, which contains cancer cells. Those cells, coupled with a high activation of STAT3, can spread to other areas … Continued
(June 9, 2016) A ten year, OCRFA-funded study has revealed the effect that the human leukocyte antigen (HLA) genes, which help regulate the body’s immune system, have on how the body responds to treatment of epithelial ovarian cancer. The scientists report that women with certain types of HLA may have an increased risk of ovarian … Continued
(May 4, 2016) Research funded in part by an OCRFA research grant to Dr. Weiping Zou at the University of Michigan has shown that the sensitivity and resistance to cancer chemotherapies is not fully explained by genomic mechanisms as it has previously thought. In fact, it may be affected by effector T cells (cells that defend … Continued
May 2, 2016 – Stand Up To Cancer (SU2C) has awarded a total of $1 million to five teams of cancer researchers to advance “innovation in collaboration” among SU2C-‐affiliated scientists. Each team, consisting of researchers from different SU2C-‐supported “Dream Teams” or research programs, will receive a grant of $200,000 to support new research projects stemming … Continued
Ovarian Cancer Research Alliance today announced the online publication of a collaborative best practices paper entitled, “Understanding Hereditary Cancer in the Era of Multi-Gene Panel Testing.” The paper offers key insights into the changing needs of individuals and family members who might be at risk for hereditary cancer. The paper also includes discussion of how … Continued
Get email updates about research news, action alerts, and ways to join the fight.
A global, Al-powered ecosystem designed to transform gynecologic cancer research—connecting patients, researchers, and clinicians to accelerate breakthroughs.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
